Stocks · News reference
8-K filing — Pulmatrix, Inc. (PULM)
Filed: 2026-08-13 AccNo: 0001493152-26-037592 Size: 294 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Eos SENOLYTIX Advances Lead Candidate MitoXcel Geropeptide PTC-2105 Toward First-In-Human Studies For Sarcopenia And Sarcopenic Obesity
Advancing PTC-2105 Toward the ClinicEos is in the preclinical stage of development of PTC-2105 and is conducting IND-enabling studies to support the initiation of first-in-human clinical trials, which will be led by
Eos SENOLYTIX CEO To Deliver Industry Keynote On Advancing Mitochondrial-Targeted Geropeptide Medicine; Co. Expects To Close Pulmatrix Merger In Q4
Eos SENOLYTIX, Inc. ("Eos" or the "Company"), a biotechnology company developing first-in-class mitochondrial-targeted gerotherapeutics designed to improve body composition, physical function, and
Pulmatrix Q2 EPS $(0.29) Up From $(0.42) YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.29) per share. This is a 30.95 percent increase over losses of $(0.42) per share from the same period last year.